Author

V. Guerrini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell signaling & trafficking· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

M. L. Gennaro· 3 shared R. Khan· 2 shared A. Garcia· 1 shared A. Yilma· 1 shared B. Prideaux· 1 shared B. Shenkoya· 1 shared C. Xue· 1 shared D. Quijada· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

M. L. Gennaro

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Pharmacological inhibition of macrophage triglyceride biosynthesis pathways does not improve Mycobacterium tuberculosis control in infected mice

J. R. Castillo, V. Guerrini, D. Quijada, S. Karanika, P. Neupane, H. Harris, A. Garcia, B. Shenkoya, A. Yilma, H. Bailey, R. Khan, M. Gopalakrishnan, M. L. Gennaro, P. C. Karakousis

This study evaluates two compounds that reduce triglyceride content in Mtb-infected macrophages but finds they do not reduce bacterial burden or inflammation in infected mice.

bioRxiv · Mar 6, 2024 · PreprintPharmacology & Toxicology

Cryptococcosis, tuberculosis, and a kidney cancer fail to fit the atherosclerosis paradigm for foam cell lipid content

V. Guerrini, B. Prideaux, R. Khan, S. Subbian, Y. Wang, E. Sadimin, S. Pawar, R. Ukey, E. A. Singer, C. Xue, M. L. Gennaro

The paper investigates lipid accumulation in foam cells across different diseases and finds that lipid content varies by disease and microenvironment.

bioRxiv · Jun 8, 2023Immunology

The anti-tubercular activity of simvastatin is mediated by cholesterol-dependent regulation of autophagy via the AMPK-mTORC1-TFEB axis

N. Bruiners, N. K. Dutta, V. Guerrini, H. Salamon, K. Yamaguchi, P. Karakousis, M. L. Gennaro

This study shows simvastatin's anti-tubercular effect is due to cholesterol inhibition, which activates AMPK, blocks mTORC1, and promotes TFEB-driven autophagy.

bioRxiv · Mar 4, 2020Immunology